193 related articles for article (PubMed ID: 35814251)
1. Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of
Armijo ME; Escalona E; Peña D; Farias A; Morin V; Baumann M; Klebl BM; Pincheira R; Castro AF
Front Pharmacol; 2022; 13():912688. PubMed ID: 35814251
[TBL] [Abstract][Full Text] [Related]
2. Amino Acid-Mediated Intracellular Ca
Amemiya Y; Nakamura N; Ikeda N; Sugiyama R; Ishii C; Maki M; Shibata H; Takahara T
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34198993
[TBL] [Abstract][Full Text] [Related]
3. Coordination of Rheb lysosomal membrane interactions with mTORC1 activation.
Angarola B; Ferguson SM
F1000Res; 2020; 9():. PubMed ID: 32518628
[TBL] [Abstract][Full Text] [Related]
4. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.
Lacher MD; Pincheira R; Zhu Z; Camoretti-Mercado B; Matli M; Warren RS; Castro AF
Oncogene; 2010 Dec; 29(50):6543-56. PubMed ID: 20818424
[TBL] [Abstract][Full Text] [Related]
5. Design of negative-regulating proteins of Rheb/mTORC1 with much-reduced sizes of the tuberous sclerosis protein complex.
Fu W; Wu G
Protein Sci; 2023 Aug; 32(8):e4731. PubMed ID: 37462942
[TBL] [Abstract][Full Text] [Related]
6. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex.
Yasuda S; Sugiura H; Katsurabayashi S; Shimada T; Tanaka H; Takasaki K; Iwasaki K; Kobayashi T; Hino O; Yamagata K
Sci Rep; 2014 Jun; 4():5155. PubMed ID: 24889507
[TBL] [Abstract][Full Text] [Related]
7. TSC2/Rheb signaling mediates ERK-dependent regulation of mTORC1 activity in C2C12 myoblasts.
Miyazaki M; Takemasa T
FEBS Open Bio; 2017 Mar; 7(3):424-433. PubMed ID: 28286738
[TBL] [Abstract][Full Text] [Related]
8. Consequences of interrupted Rheb-to-AMPK feedback signaling in tuberous sclerosis complex and cancer.
Lacher MD; Pincheira RJ; Castro AF
Small GTPases; 2011 Jul; 2(4):211-216. PubMed ID: 22145093
[TBL] [Abstract][Full Text] [Related]
9. Amino acid regulation of TOR complex 1.
Avruch J; Long X; Ortiz-Vega S; Rapley J; Papageorgiou A; Dai N
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E592-602. PubMed ID: 18765678
[TBL] [Abstract][Full Text] [Related]
10. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
11. p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.
Agarwal S; Bell CM; Taylor SM; Moran RG
Mol Cancer Res; 2016 Jan; 14(1):66-77. PubMed ID: 26385560
[TBL] [Abstract][Full Text] [Related]
12. MCRS1 binds and couples Rheb to amino acid-dependent mTORC1 activation.
Fawal MA; Brandt M; Djouder N
Dev Cell; 2015 Apr; 33(1):67-81. PubMed ID: 25816988
[TBL] [Abstract][Full Text] [Related]
13. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
16. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.
Castro AF; Rebhun JF; Clark GJ; Quilliam LA
J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
18. Structure of the TSC2 GAP Domain: Mechanistic Insight into Catalysis and Pathogenic Mutations.
Hansmann P; Brückner A; Kiontke S; Berkenfeld B; Seebohm G; Brouillard P; Vikkula M; Jansen FE; Nellist M; Oeckinghaus A; Kümmel D
Structure; 2020 Aug; 28(8):933-942.e4. PubMed ID: 32502382
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling.
Wang X; Fonseca BD; Tang H; Liu R; Elia A; Clemens MJ; Bommer UA; Proud CG
J Biol Chem; 2008 Nov; 283(45):30482-92. PubMed ID: 18676370
[TBL] [Abstract][Full Text] [Related]
20. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
